Conference Coverage

European Trial Upholds Use of Erlotinib in EGFR-Mutant Lung Cancer


 

FFROM THE ANNUAL MEETING OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY

The majority of patients who relapsed on erlotinib were switched to chemotherapy. The tolerability of erlotinib was consistent with previous studies, he noted.

The Spanish Lung Cancer Group sponsored the trial. Dr. Rosell disclosed a consultant/advisory role with Roche. Two of his coauthors reported a similar role, with one also providing expert testimony for Roche. Dr. Mok disclosed relationships with several drug companies, including AstraZeneca, Roche, Boehringer Ingelheim, and Pfizer.

Pages

Recommended Reading

Adjuvant Chemotherapy Delay Worsens Survival After Colorectal Surgery
MDedge Family Medicine
HPV-Related Oral Cancer Incidence Spikes Sharply
MDedge Family Medicine
Exemestane Prevented Breast Cancers in Postmenopausal Women
MDedge Family Medicine
Survey Highlights Survivor Care Issues
MDedge Family Medicine
Study: Flaxseed Bars Not Effective in Reducing Hot Flashes
MDedge Family Medicine
Screen Breast Cancer Patients for Depression
MDedge Family Medicine
Video Report: Recession Impacts Cancer Screening, Treatment
MDedge Family Medicine
New Cancer Patients Struggle to Get Appointments
MDedge Family Medicine
FDA Adds Warnings About High-Grade Prostate Cancer to BPH Drug Labels
MDedge Family Medicine
FDA Approves Test for HER2 Gene in Breast Cancer Tissue
MDedge Family Medicine